Showing 3871-3880 of 8924 results for "".
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- ZO Skin Health Announces New International Facultyhttps://practicaldermatology.com/news/20140219-zo_skin_health_announces_new_international_faculty/2459338/ZO Skin Health, Inc. announced the addition of a distinguished group of international physicians to its world-class multidisciplinary ZO faculty. Comprised of select p
- Ortho Dermatologics Resubmits NDA for Duobrii Lotionhttps://practicaldermatology.com/news/ortho-dermatologics-resubmits-nda-for-duobrii-lotion/2457646/Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of p
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p